The evolution of relapse of adult T cell acute lymphoblastic leukemia by Sentís, I. et al.
RESEARCH Open Access
The evolution of relapse of adult T cell
acute lymphoblastic leukemia
Inés Sentís1†, Santiago Gonzalez1,2†, Eulalia Genescà3, Violeta García-Hernández4, Ferran Muiños1, Celia Gonzalez3,
Erika López-Arribillaga1, Jessica Gonzalez4, Lierni Fernandez-Ibarrondo5, Loris Mularoni1,6, Lluís Espinosa4,




†Inés Sentís and Santiago Gonzalez
contributed equally to this work.
†Abel Gonzalez-Perez and Nuria
Lopez-Bigas are co-senior authors.
3Hematology Departments,
ICO-Hospital Germans Trias i Pujol,
Josep Carreras Research Institute,
Universitat Autònoma de Barcelona,
Badalona, Spain
4Program in Cancer Research,
Institut Hospital del Mar
d’Investigacions Mèdiques,
CIBERONC, Barcelona, Spain
1Institute for Research in
Biomedicine (IRB Barcelona), The
Barcelona Institute of Science and
Technology, Barcelona, Spain
Full list of author information is
available at the end of the article
Abstract
Background: Adult T cell acute lymphoblastic leukemia (T-ALL) is a rare disease that
affects less than 10 individuals in one million. It has been less studied than its
cognate pediatric malignancy, which is more prevalent. A higher percentage of the
adult patients relapse, compared to children. It is thus essential to study the
mechanisms of relapse of adult T-ALL cases.
Results: We profile whole-genome somatic mutations of 19 primary T-ALLs from
adult patients and the corresponding relapse malignancies and analyze their
evolution upon treatment in comparison with 238 pediatric and young adult ALL
cases. We compare the mutational processes and driver mutations active in primary
and relapse adult T-ALLs with those of pediatric patients. A precise estimation of
clock-like mutations in leukemic cells shows that the emergence of the relapse clone
occurs several months before the diagnosis of the primary T-ALL. Specifically,
through the doubling time of the leukemic population, we find that in at least 14
out of the 19 patients, the population of relapse leukemia present at the moment of
diagnosis comprises more than one but fewer than 108 blasts. Using simulations, we
show that in all patients the relapse appears to be driven by genetic mutations.
Conclusions: The early appearance of a population of leukemic cells with genetic
mechanisms of resistance across adult T-ALL cases constitutes a challenge for
treatment. Improving early detection of the malignancy is thus key to prevent its
relapse.
Keywords: T-ALL, Adult acute lymphoblastic leukemia, T-ALL evolution under
therapy, Evolution of leukemia relapse, ALL relapse
Background
Acute lymphoblastic leukemia (ALL) affects 3 children in 100,000 in the UK [1]. In the
past 5 decades, intense research on this disease has succeeded in reducing the mortal-
ity of ALL-affected children by 82% [2]. Recently, with the development of cancer gen-
omics, researchers have unraveled the most frequent somatic genetic alterations
underlying its development [3–14], and molecular subtypes, as well as their clinical
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relevance [15–22]. Genetic alterations that elicit some relapse events have also been un-
covered, and the potential role of therapy in the development of such relapse cases has
been explored [23–31].
ALL is less prevalent in adults (0.7 patients in 100,000 people [1]). Not only are there
differences in incidence among age groups, but also relapses after treatment appear
more frequently in adults (40–75% vs 15–20% among pediatric patients) [31]. Very few
studies have been dedicated to understanding the genomic roots of the emergence of
adult ALL, and in particular, of T cell ALL (T-ALL) [32–36]. There is a larger gap in
the study of the evolution of this malignancy under therapy and its relapse after treat-
ment. Therefore, important questions regarding the genomic evolution of adult T-ALL
remain unanswered. It is not entirely clear, for example, whether the same mutational
processes are involved in the onset of pediatric and adult T-ALL cases, and if the che-
motherapeutic drugs employed in the treatment leave a mutational footprint in relapse
cells, as it has been shown for pediatric cases [37]. Furthermore, while some genetic
mechanisms of resistance to treatment have been identified in pediatric ALL [26, 27], it
is not known whether these also contribute to resistance of the adult malignancy.
To explore the evolution of adult T-ALL under treatment and address these specific
questions, we profiled the whole-genome somatic mutations of 19 T-ALLs from adult
patients who relapsed after treatment (in-house cohort; Additional file 1: Table S1).
Samples were taken at the time of diagnosis (primary) and at recurrence of the malig-
nancy after treatment (relapse). We then analyzed the genomic evolution of these adult
T-ALL cases in comparison with 238 pediatric and young adult ALL cases (71 with pri-
mary and relapse samples) available in the public domain (Table 1). Known or potential
resistance mutations appear in 6 patients of the cohort. Nevertheless, our results show
that in the 19 cases the relapse is driven by genetic mutations, and that resistant cells
appear in the population of blasts several months before the diagnosis of the primary.
Results
The genomics of primary adult T-ALL
Previous studies on the genomic basis of pediatric ALL have identified somatic mutations
across cohorts of patients suffering from this disease [5–8, 10, 12, 13, 28–30, 38–41]. There-
fore, we first aimed to compare the landscape of somatic alterations observed across pri-
mary adult T-ALL with that across eight other cohorts of T- and B-ALL patients of varying
age, ranging from infancy to young adulthood, which we analyzed with a unified mutation
calling approach (Table 1; Additional file 1: Tables S1 and S2). Among cancer types, ALL
presents a relatively low somatic mutation burden [42, 43]. Nevertheless, the burden of
somatic point mutations of adult ALL cases tends to be higher than that of cases of most of
the subtypes of the pediatric malignancy, as has been previously observed [44] (Fig. 1a).
Mutations in human somatic cells are contributed to by different molecular mecha-
nisms involving the interaction of endogenous (for instance, spontaneous cytosine de-
amination or oxidative damage) and external DNA damaging agents (such as UV-light,
tobacco carcinogens, or chemotherapies) with the DNA repair machinery [42, 45–47].
The study of these mutational processes in tumors reveals the lifetime exposures of pa-
tients to potential carcinogenic agents and consequently contributes to shedding light
on the etiology of malignancies. Thus, we first asked whether the somatic mutations
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observed across nine cohorts of pediatric and adult ALL (Table 1) are contributed by
similar or different mutational processes. No clear differences are observed between the
mutational profiles of B-ALL and T-ALL (Fig. 1b, top). However, the mutational pro-
files of pediatric and adult malignancies exhibit discernible, albeit slight differences
(Fig. 1b, bottom). The same mutational processes appear to be active across pediatric
and adult T-ALL and in pediatric B-ALL (Fig. 1c; Additional file 2: Fig. S1). In particu-
lar, mutational signature 5 (SBS5), which in blood has been demonstrated to behave in
a clock-like manner [48], and has been associated with the process of hematopoietic
cell divisions [49, 50], appears as one of the main contributors of mutations in the evo-
lution of both pediatric and adult ALL.
We next asked whether the driver alterations observed across primary adult T-ALL in
the in-house cohort are different from those observed across pediatric B/T-ALL (see the
Table 1 Summary of ALL cohorts analyzed
ALL subtype cohort
name
Subtype cohort information Source^ Sequencing Type Num.
patients
DUX4-ERG Rearrangement and overexpression of
DUX4 and transcriptional deregulation
or deletion of the transcription factor
gene ERG
St. Jude WGS B-ALL 30
Infant MLL-R Infant patients with a fusion of the
N-terminus of the MLL gene with
the C-terminus of a partner gene
St. Jude WGS B-ALL 21
Ph positive Patients with the “Philadelphia”
chromosome present a translocation
of chromosomes 9 and 22. This
translocation creates the BCR-ABL
fusion
St. Jude WGS B-ALL 11
Ph-like Cell gene expression profile of the
lymphoblasts of Ph-like ALL is similar
to that of Ph positive ALL; however,
they do not present BCR-ABL1
rearrangement
St. Jude WGS B-ALL 18
Hyperdiploid Hyperdiploid patients are
characterized by multiple
chromosomal gains
St. Jude WGS B-ALL 40
Hypodiploid Hypodiploid patients are
characterized by chromosomal
losses
St. Jude WGS B-ALL 22
iAMP21 Patients with intrachromosomal
amplification of chromosome 21
St. Jude WGS B-ALL 12
T-ALL
Zhang
Patients with T cell ALL from
Zhang et al. [5] Nat Gen
St. Jude WGS T-ALL 13
T-ALL
Oshima
Patients with T cell ALL from






Patients with B cell ALL from







Patients with T cell ALL from
Li et al. [37] Blood
St. Jude WGS T-ALL 16*
T-ALL
in-house
In-house cohort In-house WGS T-ALL 19*
WGS whole-genome sequencing, WXS whole-exome sequencing
*Cohorts with primary and relapsed paired samples
#Mutations called by the authors of the original analysis; in all other cohorts, a uniform mutation calling pipeline was applied
^Source: St. Jude cohorts were defined according to their ALL subtype in different publications (see the “Methods”
section) except for the T-ALL pediatric cohort from Li et al. [37]
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“Methods” section; Fig. 1d; Additional file 2: Fig. S2; Additional file 1: Tables S3 and S4).
Mutations in some known ALL driver genes, such as NOTCH1 and FBXW7 (the E3-ligase
charged with its recognition for ubiquitination [51]), are overrepresented among both
pediatric and adult T-ALL in comparison with B-ALLs (χ2 p = 1.05 × 10−16 and χ2 p =
8.37 × 10−9, respectively). Similar overrepresentation of mutations in T-ALLs was found in
JAK3 (χ2 p = 0.004). In contrast, RAS activating mutations do not appear to be differently
represented in both ALL types (χ2 p = 0.05 and χ2 p = 0.634 for KRAS and NRAS).
Genomic alterations driving primary and relapse adult T-ALL
With the goal to study the evolution of adult T-ALL, the 19 patients in the in-house
cohort were selected specifically because they relapsed several months after treatment
(Fig. 2a; Additional file 2: Fig. S3; Additional file 1: Table S1). Seventeen of them
Fig. 1 Comparison of primary adult and pediatric ALL cases. a Clonal mutation burden (per megabase) of
primary T-ALLs of nine cohorts. Red lines represent the median mutation burden of tumors in each cohorts.
Tumors are represented as dots, sorted along the x-axis according to their mutation burden. b Mutational
profiles of primary ALLs in the nine cohorts in a uniform manifold approximation and projection (UMAP)
dimensionality reduction graph (see the “Methods” section). The UMAP was run on a matrix of the counts of all
possible tri-nucleotide changes (96) across ALL patients of all cohorts. Each dot represents a patient, colored
according to the cohort (top panel) or their age (bottom panel). c Mutational processes active across primary
ALL cohorts, represented by their mean (and standard deviation) contribution of the mutation burden of each
cohort. SBS1, SBS5, SBS2, SBS9, SBS37, SBS13, SBS36, respectively, single nucleotide substitutions signatures
1,5,2,9,37,13,36. d Rate of mutations of selected frequently mutated cancer genes across primary T-ALL cohorts.
Cohorts are clustered according to the similarity in their profile of cancer genes mutation frequency (see the
“Methods” section). The total number of patients in each cohort with mutations of each cancer gene is
represented by bars at the right side of the graph. Only genes with mutations in at least two patients are
included in the plot (for the full list see Additional file 2: Fig. S2 and Additional file 1: Tables S3 and S4)
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received the same treatment protocol (ALL-HR-11 [NCT01540812]), while the
remaining two were administered very similar protocols (LAL-07OLD and ALL-HR-
2003 [NCT00853008]). To uncover the genomic similarities and differences between
adult and pediatric T-ALL cases at relapse, we next compared the in-house cohort with
31 relapsed cases from the T-ALL Oshima and T-ALL SJ cohorts (Table 1; Additional
file 1: Tables S3 and S4). A list of potential driver events across the 19 patients in the
cohort is presented in Additional file 1: Tables S5 and S6.
Many NOTCH1 and FBXW7 mutations observed in the primary leukemias were also
present in the relapse samples (Fig. 2b; Additional file 2: Fig. S4). Intriguingly, mutations af-
fecting USP7, a known deubiquitinase of NOTCH1, were detected in 3 adult and 3 pediatric
patients, raising the possibility of yet another form of alteration of the NOTCH pathway in
leukemogenesis [52–54]. Overall, NOTCH1-affecting mutations in adults are distributed
along the protein-coding sequence in a very similar manner as those observed in pediatric
patients (Fig. 2c). Nine patients in the cohort present multiple mutations of NOTCH1 that
affect different protein domains (mostly HD and PEST), in agreement with previous reports
[55]. Interestingly, in 6 patients, different NOTCH1/FBXW7 mutations were detected in
the primary and relapse samples (Fig. 2d). These constitute examples of convergent evolu-
tion of mutations affecting the NOTCH1 pathway, also observed in eight pediatric patients
in the cohorts analyzed. This suggests that NOTCH1 mutations tend to appear late [56]
and recurrently (i.e., in several cells) during T-ALL development.
DNMT3A-affecting mutations, known to drive acute myeloid leukemias (AML), were ob-
served in three adult patients in the in-house cohort and none of the pediatric T-ALLs. In fact,
these three patients are classified as Early T-Cell Precursor (ETP), a T-ALL subtype that pre-
sents myeloid markers [33]. Similarly, PAT5 and PAT9, patients with mutations of ROBO2—
a gene associated with progression of myelodysplastic syndrome [57] to AML and recently re-
ported as mutated in pediatric ALL [58]—present the ETP phenotype. Clonal mutations of
PHF6 are overrepresented (χ2 p = 0.001) in adult T-ALLs with respect to their pediatric coun-
terparts, shared between primary and relapse samples. PHF6 is a zinc-finger transcription fac-
tor that suppresses ribosomal RNA (rRNA) transcription [32]. Loss-of-function mutations of
this gene have been shown to decrease sensitivity to glucocorticoids [59], which are part of
the standard first-line treatment of adult T-ALL patients. Interestingly, activating mutations of
the NT5C2 gene, known to elicit resistance to mercaptopurine anti-ALL treatment in
pediatric cases [26, 27], are also observed across 3 adult cases exposed to this drug (Fig. 2a),
with PAT16 bearing two mutations of NT5C2 (R238G, R367Q, see Additional file 1: Table
S5). In the relapse samples of two patients of the in-house cohort, we observed amplifications
of ABCB1, an ATP-dependent membrane transporter known to mediate multidrug resistance
in tumors [60, 61] (Additional file 2: Fig. S5). Finally, SMARCA4 mutations and deletions
were also detected across adult (2) and pediatric T-ALLs, but almost exclusively in relapse
malignancies, suggesting a potential role in resistance to treatment.
In summary, in 6 of the 19 adult patients of the in-house cohort, we were able to
identify a candidate treatment-resistance mutation.
The evolution of relapse adult T-ALL measured through mutations
We next asked how much do the mutational processes active in primary T-ALLs also
contribute to the overall burden of mutations of relapse adult T-ALLs. The
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Fig. 2 Comparison of different age groups in T cell acute lymphoblastic leukemia. a Schematic representation of
the clinical course of all patients in the in-house T-ALL cohort. Colored boxes (following the legend) at the bottom
depict common stages in this clinical course. The broken lines represent specific trajectories followed by groups of
patients, with the numbers in each trajectory. b Summary of driver mutations (single nucleotide variants, indels,
copy number variants and translocations) identified in the primary and/or relapse T-ALLs of adult and pediatric
patients. The original cohorts and age bins of the patients included in the table are indicated above it. The sample
where the mutation is identified (primary, relapse, or both) is indicated by color semicircles and circles at each cell
of the table. The total number of patients affected by mutations of each gene is indicated by the bars at the right-
side of the graph. The table contains the genes that are altered in at least two patients of the adult cohort (for full
table see Additional file 2: Fig. S4 and Additional file 1: Table S5). c Protein affecting mutations identified in
NOTCH1 gene within adult (above graph) and pediatric (below graph) T-ALLs. Multiple mutations in different
samples of a patient in the in-house are represented as dashed colored lines that connect the mutated
positions. (No line connects mutations in patients of pediatric cohorts, even if multiple mutations affecting NOTC1
in a patient were observed.) d Clonality change in multi-mutated NOTCH1 pathway genes. Blue and orange
squares depict, respectively, primary and relapse T-ALL samples of each patient. Lines connecting them represent
shared (connecting lines) or private (lines ending in a cross) NOTCH1 or FBXW7 mutations. In 5 out of 19 patients,
only one mutation in this pathway is identified, while in the other 11, multiple mutations are detected. We did not
detect any mutation affecting this pathway in only 3 of the 19 patients
Sentís et al. Genome Biology          (2020) 21:284 Page 6 of 24
incorporation of new mutational processes, like the exposure to chemotherapies used
in their treatment, could leave a mutational footprint that may be detectable in the re-
lapse clone, as recently demonstrated in metastases of different solid tumors, and in re-
lapsed pediatric ALL cases [37, 46].
The deconstruction of mutational signatures (representing mutational processes ac-
tive during a person’s life) of primary and relapse samples of each patient reveals very
similar scenarios for primary-private, shared, and relapse-private mutations (Fig. 3a).
Signature 5 (SBS5), which represents a mutational process associated with
hematopoietic cell division [46], contributes the vast majority (~ 80%) of mutations in
these three groups. We did not detect the mutational footprint of mercaptopurine or
any other chemotherapy in the relapse samples (Additional file 2: Fig. S6). This does
not preclude that chemotherapy-related mutations exist below the level of detection of
the sequencing technology, for example if the evolutionary bottleneck caused by the
treatment has not sufficiently reduced the T-ALL population.
Since signature 5 has been described as a clock-like process [48] and this type of mu-
tations are the main contribution to the burden of clonal mutations of both primary
and relapse T-ALLs, we used them to infer a molecular time of divergence between the
primary and relapse populations (Fig. 3b, Additional file 2: Fig. S7). To this end, we
counted the number of primary-private, shared, and relapse-private signature 5 clonal
mutations (Fig. 3b). In all cases, the branch that corresponds to relapse-private muta-
tions is longer than that representing primary-private mutations, because the relapse
clone has continued accumulating mutations longer after its divergence from the pri-
mary (eliminated as a consequence of the treatment). As expected, fewer relapse-
private mutations accumulate in the cases with shorter time elapsed between the diag-
nosis of the primary and the emergence of relapse.
Time of divergence of primary and relapse clones
The number of primary-private, shared, and relapse-private signature 5 clonal muta-
tions can also be used to estimate the precise time of the divergence of the primary and
relapse clonal populations. To that end, we first needed to understand the rate of accu-
mulation of signature 5 mutations during T-ALL development. The DNA of normal
hematopoietic cells has been shown to incorporate signature 5 mutations at a rate of
roughly 12 per year (Fig. 4a; Additional file 2: Fig. S7 [49]). Regressing the number of
signature 5 mutations across primary and relapse T-ALLs on the age of patients in the
in-house cohort in comparison with healthy hematopoietic stem cells (HSCs) yields
slightly higher mutation rates and an unanticipated high (~ 400) number of mutations
at the start of life of hematopoietic cells (intercept of trendline in Fig. 4a). This devi-
ation could be explained through an acceleration in the mutation rate that occurs upon
malignization of hematopoietic cells [62].
To compute the moment of time before diagnosis when this acceleration started, as
well as the value of the accelerated mutation rate, we assumed that the acceleration rate
is the same for the primary and relapse malignancies of a patient. We then simulated a
one-time increase of the mutation rate (constant rate model) during tumor evolution
and alternatively a steady increase (linear rate model) in the mutation rate for succes-
sive cell generations (Additional file 2: Fig. S8). For each patient, we assayed several
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trendlines of accelerated mutation rate (i.e., starting at different timepoints before diag-
nosis; dotted lines in Fig. 4b) approximating the observed number of signature 5 clonal
mutations in the primary and relapse T-ALL clones. We computed the likelihood of
each of these trends of acceleration following their accuracy to fit the observed number
of mutations in the primary and relapse malignancies (Fig. 4b and Additional file 2: Fig.
S8). For each trendline of accelerated mutation rate, the age of the patient at which the
divergence of the two clones occurred can be computed from the number of shared
mutations. The difference between this age and the age at diagnosis then yields the
time elapsed between this divergence and the diagnosis of the primary T-ALL.
Upon application of this approach to each patient in the in-house cohort, we ob-
tained a number of estimates of the number of days elapsed between the divergence of
both clones and the diagnosis of the primary T-ALL, each with varying likelihood
(green circles, Fig. 4c). The estimates for each patient may be summarized as their
weighted (by likelihood) averages (broken lines). The time estimated for each patient
was subsequently refined using the distribution of all patients (see the “Methods” sec-
tion). As a result, we obtained a robust prediction of the boundaries of the most likely
time elapsed between the divergence of primary and relapse clones and the diagnosis of
the primary malignancy. In the majority of cases shown in the figure (13 out of 15) less
than a year passed between the emergence of the relapse clone and the diagnosis of the
primary disease (Additional file 1: Table S7).
The evolution of relapse of adult T-ALLs
Both the primary and resistant populations of T blasts across the adult in-house T-ALL
cohort are composed of a major clone and one or more subclones detectable through
Fig. 3 Shared and private mutations in major primary and relapse T-ALL clones. a Contribution of different
mutational processes to the mutation burden of each T-ALL case in the adult cohort. The contribution to
primary-private, relapse-private, and shared clonal mutations are indicated separately in absolute (top panel)
and relative (bottom panel) terms. b Molecular evolution of adult T-ALL cases represented in a tree-form
showing the number of shared clonal mutations (green trunk), clonal private-primary (blue branch) and
clonal private-relapse (orange branch) mutations. Only signature 5 mutations are considered to build the
tree (for further explanation see Additional file 2: Fig. S7). The relative length of the trunk and branches is
proportional to the number of mutations in the respective group. Patients are sorted by decreasing order
of age
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sequencing (see Additional file 3). In all the patients, including four that are refractory
to treatment, the major clone in the primary and relapse leukemias differ, implying that
in every case, the treatment obliterates the major clone in the primary malignancy.
To understand the effect of the therapy on the clonal architecture of adult T-ALLs,
we first estimated the speed of growth of the population of T-ALL cells to determine
the minimum size of the relapse population at the time of diagnosis. This growth speed
may be characterized through the doubling time of the population (the time needed by
a population of cells to duplicate its number). This can be computed from the number
of blasts estimated by the pathologist at remission and relapse, and the amount of time
elapsed between both events [37] (Additional file 2: Fig. S9a; see the “Methods” sec-
tion). We computed a doubling time for the T-ALL leukemic population of 10.79 days
(confidence intervals, 10.1–11.36), which is slightly longer than that recently estimated
for pediatric B-ALL [37] (Additional file 2: Fig. S9b). We were then able to compute,
Fig. 4 Time of divergence between major primary and relapse T-ALL clones. a Relationship between the
mutation rate of ALL samples and the age of patients. The red line shows the regression line estimated
from the data points which are the number of mutations attributed to signature 5 (red dots are primary
sample and red crosses represent the relapse) of the in-house adult T-ALL cohort. In pink, the regression
line estimate for the pediatric primary samples (here represented as pink dots). The gray cross and triangle
correspond to the signature 5 somatic mutations from healthy tissue (MPP and HSC cells) of Osorio et al.
[49]. Pearson correlation coefficient (r) is indicated above each of the previously mentioned regression lines.
b Schematic representation of the different mutation rate increment models to estimate the divergence
time of the leukemic (primary and relapse) cells. c Divergence time of the primary and relapse clone
represented as days before diagnosis. The dots are the estimates computed from the models used and the
size of the dots represents their likelihood (see Additional file 2: Fig. S8). The dashed line is the weighted
mean of the likely model estimates (see Additional file 1: Table S7)
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with this doubling time, the minimum time necessary for the relapse population to
achieve approximately 7 × 1011 cells that corresponds to a full grown leukemia [37, 63].
This minimum time to expand from a single cell upon its divergence from the primary
population informs us of the likelihood that the relapse clone has arisen before the
diagnosis of the primary.
In three cases (PAT7, PAT11, PAT12), it is possible that the relapse clone appeared
during treatment, given the estimated doubling time. In two more (PAT9 and PAT10),
it is not completely clear whether there was enough time between the start of treatment
and relapse to allow the emergence of a new clone. In all other cases, the relapse clone
was most likely already present at the time of diagnosis and represented by more than
one cell (Fig. 5a). Indeed, for fourteen patients in the cohort, the size of the relapse
clone at the time of diagnosis of the primary malignancy probably comprises more than
100 out of the 7 × 1011 leukemia cells. (Note that this calculation is independent from
the time elapsed between divergence of the primary and relapse clones and the diagno-
sis computed previously.) PAT2, PAT4, PAT5, and PAT17, with more than 0.01% min-
imal residual disease during treatment, show estimates of the relapse clone at the time
of diagnosis which are, as expected, above 1 in 10,000 blasts. We then asked whether
the relapse clone could be detected in the primary sample of ALL cases by a method
with a lower limit of detection than Next Generation Sequencing technologies. Thus,
we aimed to detect two non-synonymous SMARCA4 mutations (G1162S and T786I)
that are private of the relapse sample of two patients in the corresponding primary
samples of these patients (PAT8 and PAT14). With a limit of detection of around one
in 1000 cells, a digital PCR was unable to detect this mutation in the primary sample of
either patient (Fig. 5a and Additional file 2: Fig. S10a,b). The fraction of cells of the re-
lapse clone estimated to be in the primary sample of these two patients is below this
limit of detection. These results thus provide further support to the estimation of the
doubling time and the size of the relapse clone in the primary samples derived from it.
Although we were able to pinpoint known or putative resistance mutations in several
cases, we asked whether other cases of relapse could be explained by a failure of the
treatment to kill a subset of the leukemic cells independent of any genetic mechanism
[28, 58]. To answer this question, we modeled the emergence of the relapse clone fol-
lowing both a resistant and a non-resistant (not driven by a genetic mutation) scenario
(Fig. 5b). First, a population of tumor cells with driver and passenger mutations was
simulated. Then, to model the first scenario, a group of cells sharing one passenger
subclonal mutation (the resistance mutation) were selected as survivors of the treat-
ment and were expanded again for 20, 40, or 60 generations (40 generations corres-
pond roughly to the observed times elapsed between primary and relapse diagnoses for
the cohort; Additional file 2: Fig. S11). To simulate the second scenario, a group of cells
with the same size as in the first case (but selected randomly and sharing no particular
subclonal mutation) was selected and expanded for the same number of generations.
We then compared the change in clonal composition—change of cancer cell fraction
(CCF) of mutations in primary and relapse—obtained for both simulated scenarios with
the distribution of CCF in the primary samples of mutations fixed in the relapse sam-
ples for all patients, represented in Fig. 5c. For example, of all mutations fixed in the re-
lapse ALL of PAT8 (dashed brown line), approximately 59% were present at CCF 0–
0.1% in the primary. In other words, in the primary sample, they appeared below the
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Fig. 5 (See legend on next page.)
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limit of detection of the sequencing and thus correspond to the red star mutations in
the toy diagrams in Fig. 5b. On the other hand, 30% of the PAT8 fixed mutations were
detected in the primary ALL at CCF between 0.9 and 1, with the remaining mutations
at intermediate CCF bins. All patients in the cohort yield similar bimodal distributions.
Only in the results of the simulation of the resistant scenario do we observe a distri-
bution of CCF of the mutations in the primary sample that resembles that of the pa-
tients in the in-house cohort (Additional file 2: Fig. S10). By contrast, in the results of
the simulations of the non-resistant scenario, no mutations undetectable in the primary
leukemia (CCF in the 0–0.1 decile) become fixed in the relapse (Fig. 5d). This holds if
the simulations are run between 20 and 60 generations, and even if a much higher (un-
realistic) fitness is assigned to driver mutations. These results suggest that the non-
resistant scenario of evolution under treatment is not feasible given the time elapsed
between primary and relapse.
In summary, in 14 cases in the cohort, the relapse population is most likely already
present before the start of the treatment. Moreover, all relapse cases fit the model of
genetic resistance—due to one genetic event common to all cells in this relapse popula-
tion—although we are only able to identify the responsible mutation in a few of them.
Discussion
Advancing our knowledge on how tumors respond to therapies and which of their fea-
tures determine their relapse after treatment is key to improving clinical oncology prac-
tice. Here, we studied the genomic features and the clonal composition of nineteen
adult T-ALL cases at diagnosis and after relapse to understand their evolution and
identify commonalities that may predict their likelihood to respond to current thera-
peutic approaches.
Our results suggest that for most adult T-ALL patients, the population of leukemia
cells that dominates the relapse is already present at the moment of diagnosis, that is
before the start of the treatment, and comprises more than one but fewer than 108
(See figure on previous page.)
Fig. 5 Evolution of relapse lymphoblast population. a Estimated size (number of cells) of the relapse
population at the time of diagnosis according to the computed doubling time. Error bars represent the
estimates of cell populations from the first and third quartile of the doubling time estimates, which are 10.1
and 11.36 respectively (see Additional file 2: Fig. S9). Horizontal dotted lines represent sizes corresponding
to one cell and 108 cells (0.01% of the population: the threshold of clinical relapse). Asterisks denote
patients with estimates above the threshold of 0.01. The resolution limit of the dPCR is also represented by
a horizontal line (~ 1:10,000). b Schematic representation of the two considered scenarios of relapse of T-
ALL patients after treatment. Mutations in T-ALL cells are represented as different geometric figures. In the
first scenario (resistant), one mutation in the primary T-ALL below the limit of detection of the sequencing
and the digital PCR (red star) provides resistance to the treatment. All cells with this mutation survive the
bottleneck posed by the treatment, and thus, this mutation and all other common to the resistant cells
(hitchhikers) appear in the relapse population at CCF 1. In the second scenario (non-resistant), a group of
cells with an ensemble of mutations survive the treatment. c Distribution (frequency) of CCF values of
mutations in primary T-ALLs in the in-house cohort that are identified in their relapse counterparts as fixed
(> 0.9 relapse CCF). Mutations are grouped within CCF bins. Each line represents one patient, for example,
the dash brown line corresponds to PAT8, discussed in the text. d Distribution (frequency) of CCF values of
mutations in synthetic primary T-ALL populations in evolutionary simulations following the non-resistant
scenario. The dots represent mutations binned at different CCF values with the frequency that each bin
represents with respect to all mutations in each synthetic relapse population. The average results of six
simulation settings with different values of fitness of driver mutations and number of cell generations
are presented
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blasts. One evidence that supports this notion comes from the fact that, in most cases,
the span of time between the diagnosis and the emergence of relapse is not enough
(given the doubling time estimated from the cohort) to explain the repopulation of a
full leukemic population starting from a single cell. This contrasts with the results re-
ported recently for a pediatric cohort, in which some relapse cases could be explained
by resistance mutations appearing during treatment [37]. This finding is relevant for
the clinical practice, since early identification of such potential resistance populations
in a patient’s leukemia may support making clinical decisions regarding their
treatment.
We were not able to detect the mutational footprint of chemotherapies employed in
the treatment of patients of this cohort, such as mercaptopurine, which has already
been characterized in pediatric T-ALL cases [37]. This does not preclude that these
chemotherapies indeed cause mutations in leukemic cells that progress in the relapse.
Since upon treatment chemotherapy mutations will be private to each blast, if the re-
lapse clone does not emerge from a complete clonal expansion after the start of the
treatment, the variant allele frequency of these treatment mutations will not rise above
the limit of detection of the sequencing. The detection in the relapse T-ALL population
[37] of these treatment mutations would require that only one or few blasts survived
the treatment, guaranteeing that sufficient numbers of cells in the relapse carried the
same mutations to make them detectable through sequencing. The absence of treat-
ment footprints in the relapse is therefore another evidence that the relapse population
at the time of treatment already contains a large number of cells.
One intriguing result is the detection of multiple mutations affecting the NOTCH
pathway in the same T-ALL case, which do not appear to be exceptions, but rather the
rule. It is possible that mutations affecting different domains of NOTCH1 increase the
fitness of leukemic cells more than a single mutation and provide an advantage for re-
lapse. Further studies comparing the pattern of NOTCH1 mutations in relapsing and
non-relapsing T-ALLs are needed to clarify this.
Conclusions
All results show that, in the T-ALL patients of this cohort, the relapse is driven by gen-
etic mutations that appear in the population of blasts several months before diagnosis,
giving rise to a resistant subclone of up to several million cells at the beginning of treat-
ment. Upon treatment thus, this subclone comes to dominate the T-ALL population at
relapse.
Methods
In-house cohort selection and samples collection
Samples from adults (≥ 18 years old) with T cell acute lymphoblastic leukemia were col-
lected in the course of 15 years under therapy protocols (LAL-07OLD, ALL-HR-03,
LAL-AR-2011) as part of the PETHEMA (Programa Español de Tratamientos en
Hematología) trials (with the exception of patient 16). Patients have signed the corre-
sponding consents of the protocols. Cohort clinical data is specified in Additional file 2:
Fig. S3 and Additional file 1: Table S1. There are three collected samples per patient:
one taken at diagnosis (primary), a second one when the percentage of lymphoblasts is
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reduced during treatment (remission), and a final sample when the leukemia reappears
after some months (relapse).
Whole genome sequencing
The short-insert paired-end libraries for the whole genome sequencing were prepared
with KAPA HyperPrep kit (Roche Kapa Biosystems) with some modifications. In short,
in function of available material 0.1 to 1.0 microgram of genomic DNA was sheared on
a Covaris™ LE220-Plus (Covaris). The fragmented DNA was further size-selected for
the fragment size of 220–550 bp with Agencourt AMPure XP beads (Agencourt, Beck-
man Coulter). The size selected genomic DNA fragments were end-repaired, adeny-
lated, and ligated to Illumina platform compatible adaptors with Unique Dual matched
indexes or Unique Dual indexes with unique molecular identifiers (Integrated DNA
Technologies). The libraries were quality controlled on an Agilent 2100 Bioanalyzer
with the DNA 7500 assay for size and the concentration was estimated using quantita-
tive PCR with the KAPA Library Quantification Kit Illumina® Platforms (Roche Kapa
Biosystems). To obtain sufficient amount of libraries for sequencing, it was necessary
for the low input libraries (0.1–0.2 μg) to amplify the ligation product with 5 PCR cy-
cles using 2x KAPA-HiFi HS Ready Mix and 10X KAPA primer mix (Roche Kapa
Biosystems).
The libraries were sequenced on HiSeq 4000 or NovaSeq 6000 (Illumina) with a
paired-end read length of 2 × 151 bp. Image analysis, base calling, and quality scoring
of the run were processed using the manufacturer’s software Real Time Analysis (HiSeq
4000 RTA 2.7.7 or NovaSeq 6000 RTA 3.3.3).
Analysis of ALL cohorts in the public domain
We downloaded public whole-genome and whole-exome sequencing data from EGA
and dbGap. We included samples from St. Jude Children’s Research Hospital associated
with EGAD00001001052 and EGAD00001001432 EGA accession codes. We have used
only samples of which we could recover clinical information from the associated publi-
cations [5, 8, 10, 38, 39]. We downloaded the DNA sequencing data of Oshima et al.,
2016 [30] from dbGap under the accession code phs001072.v1.p1. The information of
the cohorts with the clinical information gathered for each sample is summarized in
Additional file 1: Table S2.
For some of the samples, we could not find information regarding the sex of the pa-
tient. In those cases we inferred it from the normal sample BAM of each patient. For
that, we applied the following reasoning: (1) we determined that the patient is a female
if the average coverage of chromosome X is greater than the minimum average cover-
ages of the autosomal chromosomes and (2) the mean coverage of chromosome Y is 10
times smaller than the average coverage of the autosomal chromosomes of the sample.
All the samples in Additional file 1: Table S2 have been analyzed with the same pipe-
line (for detailed information see the following section: “Alignment and variant call-
ing”). However, in order to compare the T-ALL Adult cohort with other T-ALL
cohorts with pre- and post-treatment samples, we added the mutations reported in the
supplementary materials in Li et al. [37] only in Fig. 2a and b.
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Alignment and variant calling
Alignment, SNV, small InDels
We performed the alignment and calling of mutations (SNVs and small InDels) using
Sarek pipeline v2.2.1 [64]. This workflow performs the alignment from raw FASTQ ap-
plying the steps referred to as “best practices” according to GATK. We converted the
downloaded BAMs from public repositories to FASTQ with biobambam v2.0.72 and
used them as input for the pipeline. We used the Strelka caller implemented in Sarek
to generate mutation calls. Only the T-ALL adult cohort was aligned with GEM-
mapper v3.6 by the CNAG but the calls were done with Strelka. The mutation calls
were performed using primary and relapse as tumor samples and the remission as “nor-
mal” sample. Variants have been annotated with VEP v.92 run locally with the canon-
ical flag and using gnomAD r2.0.1 to get population frequencies of the potential
polymorphisms.
CNV
We have used FACETS v0.5.6 [65] to call copy number changes in WGS and WES
samples. Following FACETS documentation, we first created its input with snp-pileup
which imputed common SNPs and made the reference and alternative read counts at
nucleotide resolution. We have run snp-pileup with the recommended parameters ex-
cept for the --min-read-counts that was set to 10,0. We run FACETS for WES as men-
tioned in the documentation but setting preProcSample function parameters to cval =
15, ndepth = 5, snp.nbhd = 500 and procSample function parameters to cval = 80, min.-
nhet = 20. Similarly, we run FACETS for the WGS data as preProcSample (snp.nbhd =
5000, ndepth = 5, cval = 75) and procSample (cval = 800, min.nhet = 25).
SV
We ran Delly v0.7.9 [66] to detect duplications, inversions, and translocations. First we
ran the call function and then the filter function of Delly for each one of the alterations
mentioned. The map-quality parameter of the call function was set to 20 and we also
passed a file provided in the github of Delly with regions to exclude through the --ex-
clude argument. The filter function was run with the following parameters: --filter som-




From the VCF output from Strelka, we retained the calls labeled as PASS and DP from
the FILTER column. We recovered the shared mutations between primary and relapse
that are not PASS or DP but are present in the original VCF. This was not possible for
patients with only paired samples (primary and remission) in some cohorts. In addition,
we checked for miss-called DNVs (dinucleotide variants) by inspecting consecutive
SNV positions with Samtools v1.4.1 and changed the reference and alternative if
needed. Once the variants were annotated with VEP, we took the variants in the canon-
ical transcript. In case of more than one consequence type predicted for the same vari-
ant, we took the most damaging (more impact) one according to VEP. We also filtered
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out mutations with population frequency greater than 0.01 according to the gno-
mADg_AF column added. Finally, we discarded low coverage variants as the ones with
a total depth of 5 reads. Further details regarding filters applied to called SNVs are pro-
vided in Additional file 3.
CNV
We discarded the variants that were called with low reliability. Those are the segments re-
ported with NAs in the cellular fraction and minor allele copy number columns of FACE
TS output which, to our knowledge, indicate that the region does not have sufficient
numbers of heterozygous SNPs to guide good estimates (Additional file 2: Fig. S5).
SV
We converted the VCFs into bedpe format with bcftobedpe function from svtools
v0.4.0 and kept the variants with the flag PASS in the FILTER column. We manually
check recurrent SV that have not been described before in the literature by performing
BLAT of the breakend points (BND) and their flanking regions in the UCSC and dis-
carded those that were Alu regions or mappable to many parts of the genome.
Purity and clonality estimations
We inferred the purity of the samples from the variant allele frequency (VAF) distribu-
tion of the mutations as follows. Since the overall ploidy of the samples was mostly
around 2 (diploid), we computed density plots of the VAF multiplied by the CNV of
each mutation as a rough proxy of the CCF and determined the purity as the maximum
point. We recomputed the CCF with the inferred purity and fitted a beta binomial dis-
tribution (betabinom function from scipy v1.4.1 python package). For each mutation,
we derived a probability from it and categorized them as clonal or subclonal according
to a threshold of 0.01 (above or below it respectively). Exceptionally for PAT16, upon
inspection of the CCF distributions in primary and relapse samples, we detected a more
complex clonal structure and thus used a threshold of 0.05 for a clearer categorization
of the clonality of the mutations.
Signatures analysis
Several runs of deconstructSigs v.1.8.0 [67] were carried out depending on the context
of the analysis. Firstly, following the guidelines proposed by Maura et al. [50], we have
included all hematological meaningful described signatures for the fitting of primary
samples (see Additional file 2: Fig. S1). From those, we selected the signatures that we
believed had a substantial activity in the primary leukemias in at least one patient of
the cohort analyzed and re-run deconstructSigs with them (see Fig. 1c). Secondly, we
re-fitted the T-ALL adult samples with only those signatures that presented activity
(SBS1, SBS5, SBS18) to better estimate their contribution in Fig. 3a. Lastly, we have fit-
ted known-treatment signatures for the primary and relapse samples to see whether
there is any contribution of those in the mutational profile of the relapse. In this case,
we have included Signature 32 (SBS32) which the proposed etiology in COSMIC [68]
suggests prior treatment with azathioprine. The adult T-ALL patients have not been
treated directly with this compound but it is known that azathioprine is metabolized to
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6-mercaptopurine which is used in the maintenance phase of received therapy (see
Additional file 2: Figs. S3 and S6). Apart from SBS32, we have also included two treat-
ment signatures recently extracted in Li et al. [37] as SBSA_new and SBSB_new. They
assigned the usage of thiopurines to SBSB_new signature so that is why we have de-
cided to include it. There is not much said about SBSA_new but since pediatric and
adult ALL patients receive similar treatment we decided to give it a try in the fitting
analysis. In all cases, we set the signature cutoff parameter of deconstructSigs to 0.1.
Clustering of driver genes of ALL subtypes
The distances computed to build the dendrogram on Fig. 1d were based on Jensen-
Shannon divergence measures between the distributions of the number of patients per
mutated gene of each cohort. We only took into account genes with mutations in at
least three patients.
Dimensionality reduction
We used a Uniform Manifold Approximation and Projection (UMAP) implemented in
the python package umap-learn v0.3.10 to simplify the mutational profiles (96 dimen-
sions that represent each trinucleotide channel) into two dimensions with the size of
the local neighborhood (n_neighbors) to 20 and minimal distance (min_dist) of 0.2.
Identification of ALL driver variants
Driver gene discovery
We have run the IntOGen pipeline [69] for SNVs and small InDels (https://www.into-
gen.org/search) locally for each of the defined cohorts (see above). For each one of the
outputs, we have proceeded as follows. First, we have discarded all genes in Tier 3 and
4 that are not in the Cancer Gene Census (CGC) [70]. Second, we have discarded all
genes in all tiers that have been defined as potential artifacts (see this list of genes in
https://bitbucket.org/intogen/intogen-plus/src/master/extra/data/artifacts.json). Third,
we have manually inspected the remaining genes and defined a list of potential false
positives (FP). From this list of suspicious genes, we have discarded those not present
in the CancerMine. With the rest of the FP candidates that were present in the Cancer-
Mine, we have decided their level of credibility as driver genes of leukemia according to
the publications reported. Apart from that, we have also manually searched in PubMed
for any other missed relation by CancerMine of the gene and hematopoietic neoplasms
(see Additional file 1: Table S3).
Literature lists of cancer genes of ALL
We have defined 3 lists of known driver genes in ALL:
– Genes with SNVs/InDels mutations
– Genes affected by CNV
– Genes affected by SV that are known to drive ALL
The genes and their sources to build these lists are listed in Additional file 1: Tables
S4.a,b,c respectively.
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Annotation of alterations
For SNVs and InDels, we have defined as potential driver all the mutations with a pre-
dicted protein affecting consequence type (in the canonical transcript) according to
VEP (transcript_ablation, splice_acceptor_variant, splice_donor_variant, stop_gained,
frameshift_variant, stop_lost, start_lost, transcript_amplification, inframe_insertion,
inframe_deletion, missense_variant, protein_altering_variant, splice_region_variant, in-
complete_terminal_codon_variant, start_retained_variant, stop_retained_variant) in a
cancer gene from the list defined as the combination of the results from the Driver
Gene Discovery and the curated literature list of SNVs and InDels. Results from that
are summarized in Fig. 1d, Additional file 2: Fig. S2, and Additional file 1: Table S5.
For CNV and SV, we have flagged the alterations we have found as “known driver”
(contained in the curated literature lists respectively) or with “alteration in gene of
interest” if it affects any cancer gene related to leukemia of all the lists. In the case of
CNV affecting genes of interest, we consider as candidate drivers those oncogenes that
are fully amplified and tumor suppressors affected by any deletion. Results are reported
with the annotated “classic” Giemsa cytobands by mapping where the BND genomic
coordinates fall within them (see Additional file 1: Table S6 a and b).
We have also annotated the genes affected grouping them by some meaningful infor-
mation such as their protein family, biological process, or pathway (see Additional file
2: Figs. S2, S4 and Additional file 1: Table S4). We created those groups with informa-
tion from the sources in Additional file 1: Table S4.
Estimations of divergence time
Considering the differences between the mutational burden of T-ALL samples com-
pared with the expected number of mutations of healthy hematopoietic cells seems
clear that some acceleration on the mutation rate has occurred (Fig. 4a). Additionally,
the regression between age and signature 5 of healthy cells and T-ALL show close slope
(12.21 ∓ 1.24 vs 20.61 ∓ 6.58, see Fig. 4a and Additional file 2: Fig. S7) but a much
higher intercept (22.35 ∓ 45.53 vs 397.4 ∓ 251.81, see Fig. 4a and Additional file 2: Fig.
S7). We hypothesize these similarities on slope and differences on intersect can be ex-
plained by a late-stage acceleration during tumorigenesis that affects in a similar way
the different T-ALL samples.
Based on this hypothesis of tumorigenesis acceleration of signature 5, we have built 2
different models which represent the upper and lower boundary of the estimations: (I)
the change of mutation rate is a one-time, discontinuous event, shared between pri-
mary and relapse, and (II) the change on the mutation rate grows linearly during all
lifetime of the tumor. In both scenarios, the mutation rate can only increase and both
primary and relapse clones are under the same mutational process. In terms of diver-
gence time, the constant model is the most conservative showing the earliest times of
divergence between clones, while the linear model is the one generating larger diver-
gences times. The rest of the models based on N acceleration steps will generate esti-
mates within the previous described.
We established 120 different timepoints tn evenly spaced along the 10-year period
immediately preceding diagnosis: we refer to them as “acceleration times,” since they
are bound to represent the time-points when the mutation rate first deviates from
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neutral, clock-like behavior. For each acceleration time, we first computed a function
assigning a plausible mutation rate for each time point, consistently with either the
constant or linear model. To this end, we fitted the mutation curve to go through the
average number of mutations of primary and relapse N(t*) at the middle timepoint t*
between these two events. More specifically, the following conditions must hold:
Constant : N tð Þ ¼ N tnð Þ þ μ  t − tnð Þ
Linear : N tð Þ ¼ N tnð Þ  1þ rð Þt
 − tn
where the values of μ and r have to be determined, depending on the model used. Now
we did 100 stochastic simulations of the mutation curve by randomly sampling 0 or 1
mutations from a beta binomial distribution with a 1-day granularity, only in cases the
mutation rate per day exceeds one a smaller granularity has been used. Thus, mean
parameter μ(t) may change with time (linear model) while correlation parameter ρ =
0.0002, estimated with the dispersion observed on healthy hematopoietic stem cells de-
scribed on Osorio et al. [49], remains constant. Therefore, the number of mutations
simulated at time t is defined recursively as:
N tmð Þ∼N tm − 1ð Þ þ BetaBinom μ tmð Þ; ρ; 1ð Þ
where μ(tm) is either μ (constant model) or log(1 + r) ·N(tm − 1) (linear model). As the
100 stochastic curves generated for each hypothesis (determined by the acceleration
time and mutation rate model) cut the time levels at primary and relapse, they cast a
distribution of the possible number of mutations about the observed that yields a likeli-
hood that the hypothesis explains well the observed number of mutations at primary
and relapse. Thus, each combination of acceleration time and mutation rate model has
an associated prior likelihood. We calculated the Bayes posterior distribution using the
combinations of parameters with a higher success (likelihood) on the cohort which is
then used to select the most plausible models underlying the observation, then provide
a plausible set of divergence times weighted by the likelihood. In order to avoid the de-
viation of the divergence time estimation due to a long tail of low likelihood simula-
tions, only the more likely scenarios have been selected (10% percentile).
Doubling time and lymphoblast population estimates
The doubling time of the T cell lymphoblast population was estimated following a simi-
lar approach as in Li et al. [37]. We assumed that blast cell growth is consistent with a
logistic model, i.e., the population fraction represented by the T-lymphoblast popula-
tion as a function of time t fits a logistic function of the form:
σ t; að Þ ¼ 1þ e − atð Þ − 1
where a is the parameter of the logistic model and t is assumed to be given in standard
time units such that the T-lymphoblast subpopulation reaches 50% of the total popula-
tion at time t = 0.
Assuming the parameter a is known, the doubling time is given by the following
expression:
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TD ¼ log 2ð Þ=a
Therefore, the doubling time estimate resorts to fitting a logistic model to our data,
i.e., provide an estimate for the parameter a.
Our approach intends to provide an estimate of a that corrects for the likely incon-
sistencies between time annotations provided in the patients’ data. We make the gen-
eral assumption that some error Δti has been introduced for each patient Pi when
associating a standard time to the T-lymphoblast population measurements—mainly
due to the difficulty to estimate the initial time for paired data points with a low initial
T-lymphoblast population fraction. A standard goodness-of-fit criterion for logistic
models is given by the cross-entropy loss:
C y; ŷð Þ ¼ − 1
n
Xn
i¼1yi logŷi þ 1 − yið Þ log 1 − ŷið Þ
where y and ŷ are the observed (resp. predicted) data samples.
Our approach intends to simultaneously estimate the errors Δti and the parameter a
by minimizing the following cross-entropy loss:




þ C yi;1; ti;1;Δti
  
where C(y; t; Δt) = ylogσ(t − Δt, a) + (1 − y) log (1 − σ(t − Δt, a))
where for each patient Pi the values yi, 0 and yi, 1 are the initial (resp. final) population
fractions and the values ti, 0 and ti, 1 are the initial (resp. final) times.
Minimization of the cross-entropy L was implemented in Python with the function
“minimize” of the scipy.optimize module. For a more robust minimization, we ran it sev-
eral times with different randomly generated initial values (see Additional file 2: Fig. S9).
Upon estimation of the doubling time TD, we proceed to compute the number of
cells Nd at the time of diagnosis as a function of the time Δt elapsed between diagnosis
and relapse:
Nd ¼ NB  f  2 − Δt=TD
where NB is an estimate of the total number of bone marrow cells in adults (~ 7.5 ×
1011 cells according to [37, 63]) and f is the frequency of lymphoblasts of the biopsy.
Digital PCR analysis of SMARCA4 mutations
The dPCR analysis was performed on a QuantStudio 3D dPCR System using the manu-
facturer’s procedure and reagents (ThermoFisher Scientific). Data analysis and chip
quality were assessed using the QuantStudio 3D Analysis Suite software online.
Simulations of relapse scenarios
In order to understand how likely our observations at primary and relapse can be ob-
tained under a non-therapy selective scenario, we have performed several simulations
using a Wright-Fisher model (https://github.com/gerstung-lab/clonex).
Firstly, we have established a set of parameters based on our observations of primary
samples using a mutation rate of 10−8 and a total number of driver and passenger
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positions of 100 (0.01 fitness effect) and 150,000 respectively on a population of 106
cells. As a result, after 5000 generations, the population has fixed a number of driver
mutations ranging from 3 to 8 (mean 5.2) and 122 to 753 (mean 505.8) passengers.
Secondly, from the primary population we randomly removed between 9 × 104 and
106 cells to simulate a bottleneck effect. The resulting population has grown for 20, 40,
and 60 generations which covers our estimations about the observed dataset (10% CI
10.83–37.89 generations).
Finally, we have compared the VAF distribution at primary of those variants with a
VAF at relapse higher than 90%, considered as fixed mutations, between the observed
and simulated non-resistant scenario.
Due to the lack of fixation of low VAF variants in our simulations, two additional sce-
narios were performed under the previously described strategy: (I) A non-resistant
simulation increasing the fitness up to 0.1 (considered as high fitness, [71]) to allow for
faster fixation rates and (II) a resistant scenario where the bottleneck consists of the se-
lection of all cells sharing a low population frequency passenger mutation, defined as
resistant mutation.
Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.1186/s13059-020-02192-z.
Additional file 1. Additional tables. This file contains the supplementary tables referenced in the main text. Table
S1 contains clinical information on the adult T-ALL cohort. Table S2 contains clinical information of the public
pediatric cohorts. Table S3 contains the detected cancer genes by IntOGen. Table S4 contains the lists of ALL can-
cer genes of interest found in the literature separated in 3 subtables according to the type of alterations: SNVs and
InDels (Table S4.a), CNV (Table S4.b), SV (Table S4.c). Table S5 contains the mutations (SNVs and InDels) that we
consider as candidate drivers. Table S6 has the candidate driver CNVs (Table S6.a) and SVs (Table S6.b) of the co-
horts analyzed. Table S7 has the time of divergence estimates between primary and relapse estimated as days pre-
diagnosis of each patient.
Additional file 2. Additional figures. This file presents all supplementary figures referenced in the main text.
Additional file 3. Additional methods. Some of the filtering steps have been extended for clarification in this file.
Additional file 4. Review history.
Acknowledgements
We would like to acknowledge the contribution of Jordi Deu-Pons and Iker Reyes to the mutation calling and general
technical support of the project. We also want to mention Francisco Martínez-Jimenez for his contribution to the ana-
lysis of drivers and Oriol Pich for his help on mutational signature analysis. We are grateful to the St. Jude Children’s
Research Hospital-Washington University Pediatric Cancer Genome Project (PCGP) for permitted access to pediatric
data. Also, we would like to thank the data from Columbia University Medical Center Institutional published in Oshima
et al. [30] used in this study.
Review history
The review history is available as Additional file 4.
Peer review information
Yixin Yao was the primary editor of this article and managed its editorial process and peer review in collaboration with
the rest of the editorial team.
Authors’ contributions
A.B, JM.R., and N.L-B coordinated the project. I. S and S.G. carried out the analyses and prepared the figures. I.S.
collected public sequencing data and re-analyzed them to call mutations systematically. I.S. also did mutation calling
of the 19 ALL patient samples of the project and performed the analysis of driver and resistance mutations. S.G.
conceived and carried out the analyses of mutation rate acceleration and the development of resistance models in
different scenarios, presented in Figs. 4c and 5c and d. F.M. contributed in the design of the statistical model to
compute the doubling time. I. S, S. G, A.G.-P. and N.L.-B. participated in the design of computational analyses and in
the interpretation of the results. L. M. contributed to the mutation calling. JM.R. and E.G. collected the samples of the
adult ALL patients and provided clinical information. I.S., E.G., E.L-A, Ll.E., A.G-P, A.B., JM.R., and N.L-B. participated in
discussions of project design, patient data, and sample selection. V.G-H., L. F-I, and B. B contributed to digital PCR
experiments and data analysis. J.G. and C.G. provided technical support to the project. A.G.-P. drafted the manuscript.
I.S., S.G., A.G.-P., and N.L.-B. edited the manuscript. A.G.-P. and N.L.-B. supervised the analyses. The authors read and
approved the final manuscript.
Sentís et al. Genome Biology          (2020) 21:284 Page 21 of 24
Funding
The authors would like to thank the Asociación Española Contra el Cáncer (AECC) for financially supporting this project
(GC16173697BIGA). N.L.-B. acknowledges funding from the European Research Council (consolidator grant 682398) and
the ERDF/Spanish Ministry of Science, Innovation and Universities–Spanish State Research Agency/DamReMap Project
(RTI2018-094095-B-I00). S. G work is supported by the European Union’s Horizon 2020 research and innovation
program under the Marie Skłodowska-Curie grant agreement No. 754510. I. S is supported by FPI fellowship from
Spanish Ministry of Economy and Competitiveness (project reference SAF2015-66084-R). V.G-H. is supported by the
AECC (project reference GC16173697BIGA-9). IRB Barcelona is a recipient of a Severo Ochoa Centre of Excellence
Award from the Spanish Ministry of Economy and Competitiveness (MINECO; Government of Spain) and is supported
by CERCA (Generalitat de Catalunya).
Availability of data and materials
The raw data of the genomic sequencing of the 45 samples (primary-remission-relapse) of the patients of the in-house
cohort is deposited in the EGA repository (accession code EGAS00001004750 [72]). To facilitate reproducibility, the
code of the analysis is available here: https://github.com/bbglab/evolution_TALL_adults under Apache Software
License 2.0 (doi:https://doi.org/10.5281/zenodo.4120326 [73];). Raw sequencing data of public datasets produced by St.
Jude Children’s Research Hospital-Washington University Pediatric Cancer Genome Project (see Table 1) was obtained
from the EGA repository (accession codes EGAD00001001052 and EGAD00001001432; some BAMS corresponding to
published projects somewhere else [5, 6, 8, 10, 14, 38]). Raw sequencing data of patients included in the study by
Oshima et al. [30] (Table 1) was obtained from dbGap (phs001072.v1.p1). The somatic mutations identified in the
patients included in the study by Li et al. [37] were obtained from the Supplementary Data of the original paper.
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